During day-to-day adjustments in therapy, what is recommended when using a combo ICS-formoterol inhaler?

When managing asthma or COPD with a combination inhaler that contains an inhaled corticosteroid (ICS) and formoterol, guidance for adjusting therapy emphasizes the importance of increasing the use of the inhaler during periods of worsening symptoms. The rationale for this approach lies in the dual action of the medication: the ICS component works to reduce inflammation and control long-term symptoms, while the formoterol, a long-acting beta-agonist, provides rapid bronchodilation for quick symptom relief.

In periods when symptoms worsen, increasing the use of this inhaler can provide both immediate relief through bronchodilation and help manage underlying inflammation over time, assuming the patient is within the recommended guidelines for usage. This is especially vital in asthma management, where step-up therapy may be necessary to regain control of symptoms.

In contrast, other options do not align with standard recommendations. Stopping use altogether could lead to uncontrolled symptoms and increased risk of exacerbations. Using only the reliever inhaler would lead to inadequate management of inflammation and might not control symptoms effectively. Switching to a different therapy can also be unnecessarily complicated and may not address the immediate need for symptom relief. Hence, increasing usage during worsening symptoms is a proactive and appropriate strategy in the management of respiratory conditions.